Krystal Biotech Q3 Revenue Jumps 30% to $127.3M; Board Authorizes $400M Buyback
KRYS sits 85% above its 52-week low of $184.02.
Summary
Krystal Biotech grew Q3 product revenue 30% to $127.3M and earned $63.1M, and its board authorized up to $400M of share repurchases in October 2026.
Key Events · Earnings and Guidance · KRYS
-
Q3 Revenue Up 30% to $127.3M
Product revenue rose to $127.3M from $97.8M a year earlier, driven by Europe ($23.3M vs $4.9M) and Japan ($8.8M vs nil) launches, partly offset by lower US sales.
-
Net Income $63.1M on Tax Base Effect
Q3 net income was $63.1M versus $79.4M in Q3 2025, which included a one-time $31.4M tax benefit; pre-tax income rose 67% to $80.1M and nine-month net income reached $173.8M.
-
$400M Buyback Authorized
In October 2026 the board authorized repurchases of up to $400M of common stock with no expiration date, funded from $911.9M of cash, cash equivalents and short-term investments.
-
KB801 Enrollment Slips to 2027
EMERALD-1 enrollment in neurotrophic keratitis has progressed slower than expected; top-line results are now expected in 2027 rather than earlier.
Analysis · KRYS · Life Sciences
Revenue growth reaccelerated to 30% year over year as European and Japanese VYJUVEK launches scaled, and the company remains solidly profitable with $173.8M of nine-month net income and $246.4M of operating cash flow. The quarter's net income fell versus last year only because Q3 2025 carried a one-time $31.4M tax benefit from releasing a valuation allowance; pre-tax income actually rose 67% to $80.1M. Against that backdrop the board authorized repurchasing up to $400M of stock, a meaningful commitment for a company with $911.9M in cash and short-term investments and no debt. The main offsets are a slower-than-expected KB801 keratitis enrollment now pushed to 2027 and a newly disclosed inventorship suit over the KB407 cystic fibrosis patents.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRYS was trading at $339.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $184.02 to $382.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.